These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 8598700)

  • 21. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
    Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Argiris A; Seropian S; Cooper DL
    Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
    Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
    Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
    Lickliter JD; Begley CG; Boyd AW; Szer J; Grigg AP
    Leuk Lymphoma; 1994 Sep; 15(1-2):91-7. PubMed ID: 7532059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
    Dreger P; Marquardt P; Haferlach T; Jacobs S; Mülverstedt T; Eckstein V; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
    Br J Cancer; 1993 Nov; 68(5):950-7. PubMed ID: 7692921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
    Grigg A; Begley CG; Juttner CA; Szer J; To LB; Maher D; McGrath KM; Morstyn G; Fox RM; Sheridan WP
    Bone Marrow Transplant; 1993; 11 Suppl 2():23-9. PubMed ID: 8334435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
    Tendas A; Cupelli L; Bruno A; Niscola P; De Angelis V; Datturi T; Cantoni F; De Meis I; Dentamaro T; de Fabritiis P
    Blood Transfus; 2012 Oct; 10(4):561-2. PubMed ID: 22395357
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
    Salloum E; Jillella AP; Nadkarni R; Seropian S; Hu GL; D'Andrea E; Zelterman D; Cooper DL
    Cancer; 1998 Apr; 82(8):1506-12. PubMed ID: 9554528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
    Sheridan WP; Begley CG; Juttner CA; Szer J; To LB; Maher D; McGrath KM; Morstyn G; Fox RM
    Lancet; 1992 Mar; 339(8794):640-4. PubMed ID: 1371817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial.
    Szer J; Curtis DJ; Bardy PG; Grigg AP
    Aust N Z J Med; 1999 Aug; 29(4):487-93. PubMed ID: 10868525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
    Vellenga E; van Agthoven M; Croockewit AJ; Verdonck LF; Wijermans PJ; van Oers MH; Volkers CP; van Imhoff GW; Kingma T; Uyl-de Groot CA; Fibbe WE
    Br J Haematol; 2001 Aug; 114(2):319-26. PubMed ID: 11529850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Martín A; Pérez-Simón JA; Caballero MD; López-Holgado N; Vázquez L; del Cañizo MC; San Miguel JF
    Haematologica; 2005 Jan; 90(1):78-85. PubMed ID: 15642673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
    Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.